Immunotherapy improves survival of patients with locally advanced head and neck cancer
Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the treatment of resectable locally advanced […]
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can control the disease for extended […]
Novel Lymphoma Clinical Trials Underway
In just the past five years, the development of new therapeutics has changed the paradigm for the treatment of lymphomas, thereby improving outcomes and quality of life. As research continues, a major goal is to find more tolerable treatment options with higher efficacy. At Siteman Cancer Center, 35 open clinical trials are investigating novel immunotherapies, […]
First-in-human clinical trials at Siteman Cancer Center to evaluate universal CAR T-cell therapies
This summer, the latest generation of CAR T-cell therapies for patients diagnosed with lymphoma, myeloma or leukemia get underway in clinical trials at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The cancer center was one of the first in the U.S. to offer CAR T-cell therapy for the treatment […]